
Intensity Therapeutics, Inc. to Present at the New York Biotech's Annual Healthcare Conference

Norwalk, CT. – May 23, 2013- Intensity Therapeutics, Inc. (private) announced that President and CEO Lewis H. Bender will present at the Annual New York Biotech Conference on Wednesday, May 29, 2013 at Marriott Marquis Hotel, in New York City. Mr. Bender will provide an overview of the Company at 10:40 a.m. (EST) in the hotel's Schubert room, located on the sixth floor. Mr. Bender will be available for one-on-one meetings with investors participating in conference before and after his presentation.

About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a specialty pharmaceutical company whose mission is to greatly extend the lives of patients with solid tumor cancers. Late stage cancer consists of well-defined visible tumors and unseen micro-metastases. To have an effective treatment one must destroy both the existing large observable tumors as well as the unseen micrometastases. Intensity Therapeutics is developing such a treatment approach. The Company creates novel, proprietary formulations of proven chemotherapy drugs. The technology increases the drug's tissue dispersion and cell penetration properties. These products when injected directly into the primary tumor and the major visible metastases result in significantly greater survival compared to conventionally delivered chemotherapy. Further information can be found at www.intensitytherapeutics.com

Contact:

Media & Investors:
Lewis Bender
President & CEO
40 Richards Avenue
Norwalk, CT 06854
Tel. (203) 604-6858
Email: lbender@intensitytherapeutics.com